{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:03:32Z","timestamp":1781327012765,"version":"3.54.1"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world population. In this interim, the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the pandemic impact in some countries and the BCG vaccine offers significant advantages and flexibility in the way clinical vaccines are administered. BCG vaccination is a highly cost-effective intervention against tuberculosis (TB) and many low-and lower-middle-income countries would likely have the infrastructure, and health care personnel sufficiently familiar with the conventional TB vaccine to mount full-scale efforts to administer novel BCG-based vaccine for COVID-19. This suggests the potential for BCG to overcome future barriers to vaccine roll-out in the countries where health systems are fragile and where the effects of this new coronavirus could be catastrophic. Many studies have reported cross-protective effects of the BCG vaccine toward non-tuberculosis related diseases. Mechanistically, this cross-protective effect of the BCG vaccine can be explained, in part, by trained immunity, a recently discovered program of innate immune memory, which is characterized by non-permanent epigenetic reprogramming of macrophages that leads to increased inflammatory cytokine production and consequently potent immune responses. In this review, we summarize recent work highlighting the potential use of BCG for the treatment respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials. In situations where no other specific prophylactic tools are available, the BCG vaccine could be used as a potential adjuvant, to decrease sickness of SARS-CoV-2 infection and\/or to mitigate the effects of concurrent respiratory infections.<\/jats:p>","DOI":"10.3389\/fimmu.2021.632478","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T04:17:34Z","timestamp":1615177054000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["The BCG Vaccine for COVID-19: First Verdict and Future Directions"],"prefix":"10.3389","volume":"12","author":[{"given":"Maria","family":"Gonzalez-Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Sanchez-Tarjuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estanislao","family":"Nistal-Villan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ochando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2666-5247(20)30032-X","article-title":"Zoonotic tuberculosis: a complex issue of the Mycobacterium tuberculosis complex","volume":"1","author":"Vitale","year":"2020","journal-title":"Lancet Microbe."},{"key":"B2","unstructured":"History of BCG vaccine538\n            LucaS\n            MihaescuT\n          Maedica.82013"},{"key":"B3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jama.1932.02740630066039","article-title":"Rapports et documents provenant des divers pays (la France except\u00e9e) transmis \u00e0 l'Institut Pasteur en (1932)","volume":"99","year":"1932","journal-title":"J Am Med Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1136\/bmj.321.7274.1435","article-title":"Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa","volume":"321","author":"Kristensen","year":"2000","journal-title":"BMJ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1016\/S0264-410X(03)00181-6","article-title":"BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?","volume":"21","author":"Garly","year":"2003","journal-title":"Vaccine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.vaccine.2004.09.006","article-title":"Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study","volume":"23","author":"Stensballe","year":"2005","journal-title":"Vaccine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3143\/geriatrics.42.34","article-title":"[Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations]","volume":"42","author":"Ohrui","year":"2005","journal-title":"Nihon Ronen Igakkai Zasshi."},{"key":"B8","unstructured":"The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly18590\n            Wardhana\n            DatauEA\n            SultanaA\n            MandangVV\n            JimE\n          21979284Acta Med Indones.432011"},{"key":"B9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","article-title":"Non-specific effects of BCG vaccine on viral infections","volume":"25","author":"Moorlag","year":"2019","journal-title":"Clin Microbiol Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell."},{"key":"B12","unstructured":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2020.08.051","article-title":"Activate: randomized clinical trial of BCG vaccination against infection in the elderly","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell."},{"key":"B17","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.xcrm.2020.100073","article-title":"Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a Retrospective Cohort Study","volume":"1","author":"Moorlag","year":"2020","journal-title":"Cell Rep Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.chom.2011.04.006","article-title":"Trained immunity: a memory for innate host defense","volume":"9","author":"Netea","year":"2011","journal-title":"Cell Host Microbe."},{"key":"B19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.ai.2016.10.001","article-title":"About training and memory: NK-cell adaptation to viral infections","volume":"133","author":"Hammer","year":"2017","journal-title":"Adv Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1251086","DOI":"10.1126\/science.1251086","article-title":"Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity","volume":"345","author":"Saeed","year":"2014","journal-title":"Science."},{"key":"B21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000355628","article-title":"Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity","volume":"6","author":"Kleinnijenhuis","year":"2014","journal-title":"J Innate Immun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","article-title":"BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity","volume":"23","author":"Arts","year":"2018","journal-title":"Cell Host Microbe."},{"key":"B23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against COVID-19?","volume":"20","author":"O'Neill","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"151600","DOI":"10.1016\/j.anndiagpath.2020.151600","article-title":"Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine","volume":"48","author":"Nuovo","year":"2020","journal-title":"Ann Diagn Pathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clim.2014.10.005","article-title":"BCG-induced trained immunity in NK cells: role for non-specific protection to infection","volume":"155","author":"Kleinnijenhuis","year":"2014","journal-title":"Clin Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"15443","DOI":"10.1038\/srep15443","article-title":"Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations","volume":"5","author":"Abdallah","year":"2015","journal-title":"Sci Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/mt.2015.216","article-title":"Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"29076","DOI":"10.1038\/srep29076","article-title":"Loss of lipid virulence factors reduces the efficacy of the BCG vaccine","volume":"6","author":"Tran","year":"2016","journal-title":"Sci Rep."},{"key":"B30","volume-title":"Report on BCG Vaccine Use for Protection against Mycobacterial Infections Including Tuberculosis, Leprosy, and Other Nontuberculous Mycobacteria (NTM) Infections","author":"Secretariat","year":"2017"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/all.14345","article-title":"Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?","volume":"75","author":"Gursel","year":"2020","journal-title":"Allergy."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/all.14344","article-title":"Is BCG vaccination affecting the spread and severity of COVID-19?","volume":"75","author":"Ozdemir","year":"2020","journal-title":"Allergy."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(20)31025-4","article-title":"Considering BCG vaccination to reduce the impact of COVID-19","volume":"395","author":"Curtis","year":"2020","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2020.8189","article-title":"SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults","volume":"323","author":"Hamiel","year":"2020","journal-title":"JAMA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17720","DOI":"10.1073\/pnas.2008410117","article-title":"BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)","volume":"117","author":"Escobar","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B36","doi-asserted-by":"publisher","first-page":"25205","DOI":"10.1073\/pnas.2015234117","article-title":"The bacillus Calmette-Gu\u00e9rin vaccination allows the innate immune system to provide protection from severe COVID-19 infection","volume":"117","author":"Patella","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.10.419044","article-title":"A single dose, BCG-adjuvanted SARS-CoV-2 vaccine induces Th1-polarized immunity and high-titre neutralizing antibodies in mice","author":"Counoupas","year":"2020","journal-title":"bioRxiv. [pre-print]"},{"key":"B38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1525-1470.2012.01848.x","article-title":"Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin","volume":"30","author":"Salem","year":"2013","journal-title":"Pediatr Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3389\/fimmu.2019.00923","article-title":"Priming with recombinant BCG expressing novel HIV-1 conserved mosaic immunogens and boosting with recombinant ChAdOx1 is safe, stable, and elicits HIV-1-specific T-cell responses in BALB\/c mice","volume":"10","author":"Kilpel\u00e4inen","year":"2019","journal-title":"Front Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3389\/fimmu.2018.00643","article-title":"Development of a live recombinant BCG expressing human immunodeficiency virus type 1 (HIV-1) gag using a pMyong2 vector system: potential use as a novel HIV-1 vaccine","volume":"9","author":"Kim","year":"2018","journal-title":"Front Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/S0264-410X(03)00256-1","article-title":"Immunization with recombinant Calmette-Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice","volume":"21","author":"Uno-Furuta","year":"2003","journal-title":"Vaccine."},{"key":"B42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4049\/jimmunol.1300118","article-title":"Immunization with a recombinant bacillus Calmette-Guerin strain confers protective Th1 immunity against the human metapneumovirus","volume":"192","author":"Palavecino","year":"2014","journal-title":"J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1080\/21645515.2017.1334026","article-title":"A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus","volume":"13","author":"Rey-Jurado","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1016\/j.vaccine.2007.01.087","article-title":"Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine","volume":"25","author":"Dennehy","year":"2007","journal-title":"Vaccine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.urolonc.2008.12.017","article-title":"The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer","volume":"28","author":"Andrade","year":"2010","journal-title":"Urol Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1084\/jem.178.1.197","article-title":"Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine","volume":"178","author":"Stover","year":"1993","journal-title":"J Exp Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1084\/jem.188.5.845","article-title":"Recombinant Mycobacterium bovis bacillus Calmette-Gu\u00e9rin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies","volume":"188","author":"Matsumoto","year":"1998","journal-title":"J Exp Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1086\/514140","article-title":"Recombinant bacille Calmette-Gu\u00e9rin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia","volume":"176","author":"Zhu","year":"1997","journal-title":"J Infect Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4049\/jimmunol.168.2.919","article-title":"Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination","volume":"168","author":"Ota","year":"2002","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1016\/j.vaccine.2019.03.016","article-title":"The influence of neonatal Bacille Calmette-Guerin (BCG) immunisation on heterologous vaccine responses in infants","volume":"37","author":"Zimmermann","year":"2019","journal-title":"Vaccine."},{"key":"B51","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1128\/JVI.01505-14","article-title":"Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection","volume":"88","author":"Channappanavar","year":"2014","journal-title":"J Virol."},{"key":"B52","unstructured":"2020"},{"key":"B53","year":""},{"key":"B54","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant bacille calmette-guerin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1008404","DOI":"10.1371\/journal.ppat.1008404","article-title":"New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia","volume":"16","author":"Taranc\u00f3n","year":"2020","journal-title":"PLoS Pathog."},{"key":"B56","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/pr.2016.142","article-title":"Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial","volume":"80","author":"Kj\u00e6rgaard","year":"2016","journal-title":"Pediatr Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/adc.2009.157537","article-title":"The non-specific effects of vaccines","volume":"95","author":"Shann","year":"2010","journal-title":"Arch Dis Child."},{"key":"B58","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/ije\/dyw120","article-title":"Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010","volume":"46","author":"Rieckmann","year":"2017","journal-title":"Int J Epidemiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1473-3099(15)00400-4","article-title":"Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study","volume":"16","author":"Nguipdop-Djomo","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1289\/ehp.908671","article-title":"Results of NTP-sponsored mouse cytogenetic studies on 1,3-butadiene, isoprene, and chloroprene","volume":"86","author":"Shelby","year":"1990","journal-title":"Environ Health Perspect."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e145157","DOI":"10.1172\/JCI145157","article-title":"BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers","volume":"131","author":"Rivas","year":"2021","journal-title":"J Clin Invest."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3389\/fimmu.2019.01317","article-title":"The humoral immune response to BCG vaccination","volume":"10","author":"Tanner","year":"2019","journal-title":"Front Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e01686","DOI":"10.1128\/mBio.01686-16","article-title":"Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis","volume":"7","author":"Perdomo","year":"2016","journal-title":"mBio."},{"key":"B65","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.vaccine.2016.12.048","article-title":"A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice","volume":"35","author":"Cespedes","year":"2017","journal-title":"Vaccine."},{"key":"B66","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.4049\/jimmunol.0903452","article-title":"Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection","volume":"185","author":"Cautivo","year":"2010","journal-title":"J Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"fnz136","DOI":"10.1093\/femsle\/fnz136","article-title":"Oncolytic bacteria: past, present and future","volume":"366","author":"Rius-Rocabert","year":"2019","journal-title":"FEMS Microbiol Lett."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.3389\/fimmu.2018.02936","article-title":"Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations","volume":"9","author":"S\u00e1nchez-Ram\u00f3n","year":"2018","journal-title":"Front Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T04:17:51Z","timestamp":1615177071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2021.632478"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.632478","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"article-number":"632478"}}